Data for Oncopeptides' melflufen could support broader MM label

Oncopeptides remains on track to submit an NDA in 1Q20 for melflufen to treat multiple myeloma, as the latest data from a pivotal Phase II study showed an overall response rate of

Read the full 324 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE